TickerTalks
Browse all tickers →
TickerTalks›$TAK
TATAK

Takeda Pharmaceutical Company Limited

$TAK·$56B·Drug Manufacturers - Specialty & Generic·Healthcare
$17.63+1.4%1Y+19.1%
Mentions · last 7 days
2026-08-08: 1 posts2026-08-09: 3 posts2026-08-10: 14 posts2026-08-11: 2 posts2026-08-12: 5 posts2026-08-13: 7 posts2026-08-14: 2 posts36+15%
Price updated 1d ago·X counts updated 21h ago
TATAK
$TAKTakeda Pharmaceutical Company Limited
$17.63+1.38%36 posts+15%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $TAK, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersAcceleratingAI verdict · as of 2026-08-14

The move is getting stronger, with heavier trading behind it.

Pharma Q1 +10% growth + fresh FDA approval for ORZEYFUL (first-and-only underlying-cause Narcolepsy Type 1 drug) — generic erosion is the offset.

Takeda Pharmaceutical is the Japanese pharma giant whose Q1 print showed 10.2% revenue growth on specific narcolepsy-and-broader-pipeline execution — with the fresh FDA approval of ORZEYFUL (oveporexton) as the first and only medicine to treat the underlying cause of Narcolepsy Type 1. Up 18% year-over-year.

  • The Q1 print showed decisive growth: revenue of JPY 1.22T grew 10% year-over-year with a 67% gross margin and 17% operating margin — the specific pharma-giant profile that reflects continued portfolio execution across the current cycle.
  • The ORZEYFUL FDA approval is the load-bearing pipeline catalyst: the specific first-and-only approval for underlying-cause treatment of Narcolepsy Type 1 represents specific-mechanism commercial expansion — the type of specific-drug approval that supports continued upside as commercial launch progresses.
  • The "major milestone with holistic narcolepsy drug approval" framing reflects the specific commercial-catalyst impact: the specific approval represents a specific-magnitude pipeline milestone that positions Takeda in a specific new therapeutic category.
  • The generic erosion is the specific near-term overhang: pipeline commentary noting generic erosion as a near-term concern reflects specific patent-cliff pressure — the type of specific structural headwind that requires the ORZEYFUL launch to actually offset.

Coming into Oct 29 earnings, the tape needs continued 10%+ revenue growth, specific ORZEYFUL launch commentary, and any additional pipeline-approval updates. A clean beat plus visible ORZEYFUL commercial traction extends the setup off the current 74%-of-range position; any generic-erosion acceleration or ORZEYFUL launch-slippage is what would compress the setup even with the recent approval.

What to watch: Oct 29 Q2 earnings — continued 10%+ revenue growth, specific ORZEYFUL launch commentary, and any additional pipeline-approval updates. Any generic-erosion acceleration or ORZEYFUL launch-slippage compresses the setup even with the recent approval.

On the calendar: 2026-10-29 — Q2 earnings

no sentiment

Read the AI verdict + X sentiment for $TAK

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Japanese global pharma company focusing on rare disease, oncology, neuroscience, and GI drugs after the $62B Shire acquisition.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - Specialty & Generic sits in its cycle right now — and what that implies for $TAK.

Drug Manufacturers - Specialty & Generic · Healthcare

No material change from last week — animal health revenues under pressure from inflation-driven vet visit deferrals while a securities fraud investigation adds governance overhang; the key debate..

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+48.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
48.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
2.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
10.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
7.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
2.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
62.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 30, 2026$0.23$0.17+33.2%
Q1 2026May 13, 2026$-0.05$0.21-123.4%
Q4 2025Jan 29, 2026$0.21$0.55-61.3%
Q3 2025Oct 30, 2025$-0.02$0.44-105.7%
Next earningsThu, Oct 29·consensus EPS $0.26

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.22T+10.2%66.7%16.5%$35.83$73.8B
Q4 FY25$1.11T+5.8%48.8%4.3%$-7.92$10.1B
Q3 FY25$1.21T+6.0%54.4%16.0%$33.40$150.9B
Q2 FY25$1.11T-5.4%65.8%6.2%$-3.74$325.4B

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$4.69T$4.55T – $4.88T$61.80$52.92 – $77.078
FY28$4.76T$4.65T – $4.88T$100.46$45.54 – $146.679
FY29$4.89T$4.74T – $5.09T$125.33$120.31 – $132.024
FY30$5.20T$5.04T – $5.41T$140.89$135.25 – $148.424
FY31$5.25T$5.09T – $5.47T$164.06$157.48 – $172.823

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.79%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+6.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+7.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 3.2B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.095-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellAug 11Shannon Elaine MaryPres., Global Supply & Quality20.4K sh$357KSellAug 10Plump Andrew StewartPresident165.4K sh$2.8MSellAug 10Farajallah Awny Samaan BotrosChief Medical Officer14.0K sh$240KSellAug 10Ibrahim Ramy Riad AhmedPresident7.3K sh$124KSellAug 10Pacheco Rhonda JanicePresident16.9K sh$289KSellAug 10Duprey Lauren RusckowskiChief Transformation Officer47.6K sh$814KSellAug 10Pignagnoli Agosti MarcelloHead, Strat. & Port. Dev23.0K sh$393KSellAug 10Bitetti Teresa MariePresident50.0K sh$855KSellAug 10Shannon Elaine MaryPres., Global Supply & Quality4.0K sh$68KSellAug 10Gabriele RicciChief Data & Tech. Officer25.1K sh$429K
1–10 of 14
+ 20 other (13 awards · 7 returns) in window

See when $TAK insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsJul 63
AI summary

Takeda Pharmaceutical (TAK) filed a Form 3 initial statement of beneficial ownership for a newly appointed Director. The filing records the director's initial holdings in Takeda ADRs as required upon board appointment.

3New insider — initial holdingsJul 63
AI summary

Takeda Pharmaceutical (TAK) filed a second Form 3 initial statement of beneficial ownership for another newly appointed Director. Specific security amounts are in the tabular section of the form.

3New insider — initial holdingsJul 63
AI summary

Takeda Pharmaceutical (TAK) filed a third Form 3 initial statement of beneficial ownership for another newly appointed Director. Specific security amounts are in the tabular section of the form.

3New insider — initial holdingsMay 53
3New insider — initial holdingsApr 63
3New insider — initial holdingsApr 63
3New insider — initial holdingsApr 63
3New insider — initial holdingsMar 183
+ 51 other (25 6-Ks · 23 3s · 1 IRANNOTICE · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Takeda's Pipeline Looks Encouraging, But Generic Erosion Is A Near-Term Concernseekingalpha.com·9d agoTakeda Achieves Major Milestone With Holistic Narcolepsy Drug Approvalbenzinga.com·9d agoU.S. FDA Approves Takeda's ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1businesswire.com·10d agoUS FDA approves Takeda's sleep disorder pillreuters.com·10d agoTakeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcriptseekingalpha.com·16d ago

More in Drug Manufacturers - Specialty & Generic

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ACB$ZYBT$ETON$EMBC$ELAN$RGC$LNTH$BHC
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport